Clinical Symptoms of Postburn Hypertrophic Scars and Analysis of Risk Factors for Itching and Pain Requiring Pharmacological Intervention.

Background: Pruritus and pain symptoms secondary to hypertrophic scars (HTSs) are associated with multiple factors, with age, body mass index (BMI), and scar thickness being the main risk factors (RFs).

Objective: This study mainly discusses the clinical symptoms associated with postburn HTSs and analyzes RFs for itching and pain requiring pharmacological intervention.

Materials And Methods: All clinical data of 93 patients with postburn HTSs who visited the Burn Department of Shanghai Seventh People's Hospital between January 1, 2021 and January 1, 2023 were collected and analyzed retrospectively.

[Effect of transfection of recombinant human endothelial nitric oxide synthase gene on hypertrophic scar fibroblasts in vitro].

Objective: To investigate the feasibility of transfection of recombinant human endothelial nitric oxide synthase (eNOS) into human hypertrophic scar fibroblasts (HSFbs), and to observe NO secretion and the synthesis of collagen I and III.

Methods: Recombinant human eNOS with karyocyte expressive vector was constructed in vitro, then was transfected into HSFbs which was isolated from hypertrophic scar tissues and cultured in vitro (T group). The HSFbs untransfected (normal culture) or transfected with empty-vector was used as control group and empty-vector group respectively.

[Effect of nerve growth factor on the promotion of sensory recovery of large skin graft in patients].

Objective: To analyze the influence of topical application of nerve growth factor (NGF) on nerve ending regeneration of large skin grafts in patients.

Methods: Sixty wounds from 48 adult patients with small or moderate burn area and scar excision were randomly divided into NGF and control groups, with 30 wounds in each group. The wounds in control group were treated with simple saline solution, while those in NGF group, the graft was first wrapped in a piece of gauze holding 100 ml saline solution containing 9000 AU NGF before operation, and then flushed with same amount of NGF saline underneath skin after application of the graft.